2022 by John Wiley & Sons, Inc.
Edition History Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulations: Principles, Methods, and Applications in the Pharmaceutical Industry, 1st Edition, © 2012 by John Wiley & Sons, Inc.
All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by law. Advice on how to obtain permission to reuse material from this title is available at http://www.wiley.com/go/permissions.
The right of Sheila Annie Peters to be identified as the author of this work has been asserted in accordance with law.
Registered Office John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, USA
Editorial Office 111 River Street, Hoboken, NJ 07030, USA
For details of our global editorial offices, customer services, and more information about Wiley products visit us at www.wiley.com.
Wiley also publishes its books in a variety of electronic formats and by print‐on‐demand. Some content that appears in standard print versions of this book may not be available in other formats.
Limit of Liability/Disclaimer of Warranty In view of ongoing research, equipment modifications, changes in governmental regulations, and the constant flow of information relating to the use of experimental reagents, equipment, and devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for each chemical, piece of equipment, reagent, or device for, among other things, any changes in the instructions or indication of usage and for added warnings and precautions. While the publisher and authors have used their best efforts in preparing this work, they make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of merchantability or fitness for a particular purpose. No warranty may be created or extended by sales representatives, written sales materials, or promotional statements for this work. The fact that an organization, website, or product is referred to in this work as a citation and/or potential source of further information does not mean that the publisher and authors endorse the information or services the organization, website, or product may provide or recommendations it may make. This work is sold with the understanding that the publisher is not engaged in rendering professional services. The advice and strategies contained herein may not be suitable for your situation. You should consult with a specialist where appropriate. Further, readers should be aware that websites listed in this work may have changed or disappeared between when this work was written and when it is read. Neither the publisher nor authors shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages.
Library of Congress Cataloging‐in‐Publication Data Names: Peters, Sheila Annie, author. Title: Physiologically based pharmacokinetic (PBPK) modeling and simulations : principles, methods, and applications in the pharmaceutical industry / Sheila Annie Peters. Description: Second edition. | Hoboken, NJ : Wiley, 2021. | Includes bibliographical references and index. Identifiers: LCCN 2021038143 (print) | LCCN 2021038144 (ebook) | ISBN 9781119497684 (hardback) | ISBN 9781119497769 (adobe pdf) | ISBN 9781119497790 (epub) Subjects: MESH: Pharmacokinetics | Drug Design | Models, Biological Classification: LCC RM301.5 (print) | LCC RM301.5 (ebook) | NLM QV 38 | DDC 615.7–dc23 LC record available at https://lccn.loc.gov/2021038143 LC ebook record available at https://lccn.loc.gov/2021038144
Cover Design: Wiley
Cover Image: Courtesy of Sheila Annie Peters
To my readers whose tremendous support for the first edition inspired me to give my best to this edition.
PREFACE TO THE SECOND EDITION
I am excited to bring out this much improved second edition, encouraged by the success of the first edition of “Physiologically‐Based Pharmacokinetic (PBPK) Modeling and Simulations: Principles, Methods, and Applications in the Pharmaceutical Industry”. The applications of PBPK modeling and simulations have exponentially grown since the publication of the first edition of the book in 2012. Since that time, a surge in PBPK regulatory submissions has prompted the regulatory agencies to release guidelines for the reporting of PBPK modeling results that accompany submissions.
The adverse impact of the COVID‐19 pandemic on global economies is still being evaluated. Pharma companies have had their fair share of losses too. Clinical studies for various indications have been affected by stretched healthcare infrastructure, recruitment challenges, lockdown, logistics issues, and confounding disease influence on outcomes. Along with World Health Organization's SOLIDARITY trial and Institut national de la santé et de la recherche médicale (INSERM)'s Discovery trial, nearly thousand clinical studies related to COVID‐19 have been registered worldwide in the first half of 2020. In a race against time to bring innovative medicines to the market, a heightened need for Model‐Informed Drug Development (MIDD) and the totality of evidence it advocates has become apparent. The applications of PBPK modeling, an important component of MIDD, supporting dose optimization and assessment of benefit‐risk ratios have been further catalyzed by the pandemic.
The book is intended to serve the interests of a broad and diverse audience from academia, industry, and regulatory agencies. Similar to the first edition of the book, this second edition has a section that covers the principles underlying pharmacokinetics, drug interactions, and physiological modeling of pharmacokinetic processes as well as interindividual variability for small molecule drugs and biologics. The second part exposes the reader to the powerful applications of PBPK modeling along the value chain in drug discovery and development. To facilitate potential use of the book in courses or workshops, a new third section providing case studies in the different areas of application of PBPK modeling has been introduced in this edition at the request of readers and reviewers. Most of these case studies are built using PK‐Sim®, a comprehensive software tool within the Open Systems Pharmacology Suite for the physiologically based pharmacokinetic modeling of small and large molecules.
In addition to introducing a third section to the book, this second edition simplifies complex topics and provides a balanced view of the vast potential of PBPK modeling alongside current challenges. Section‐I provides substantially revised and reordered content with updated literature in all chapters. A new chapter has been added on Nonclinical, Clinical and Model Informed Drug Development. Chapters in Section‐II are entirely new and focus on the vast array of applications in the field. Two‐thirds of the figures in the second edition are either revised or new.
I hope that the inclusion of recent advances in PBPK modeling and the revisions made in the current edition will serve to benefit and engage the readers.
PREFACE TO THE FIRST EDITION
Physiologically-based pharmacokinetic (PBPK) modelling has made rapid strides in the pharmaceutical industry in the last decade or so, thanks to an increasing awareness of the potential applications of this
